Dermatologic implications of glucagon-like peptide-1 receptor agonist medications
Retatrutide is a triple agonist that activates three receptors: GLP-1, GIP, and glucagon
Ideal Candidates: Adults over 35-40 with significant weight to lose (30+ pounds) and declining natural hormone levels Individuals who have tried multiple conventional approaches without sustained success Those with metabolic syndrome or prediabetes seeking aggressive intervention People prioritizing body composition (muscle-to-fat ratio) over simple scale weight Patients willing to commit to regular bloodwork, medical supervision, and lifestyle modifications Poor Candidates: Anyone with personal or family history of medullary thyroid cancer or MEN2 syndrome Individuals with active cancer or history of hormone-sensitive cancers Those with severe kidney or liver disease Pregnant or breastfeeding women People seeking a quick fix without commitment to lifestyle change Anyone unwilling or unable to afford ongoing costs and monitoring Accessing These Compounds in Canada The regulatory landscape for these compounds in Canada differs from the United States and creates specific considerations for Canadian residents interested in this protocol
In 2022, there was a shortage of GLP-1 medications, which in turn led the FDA to allow compounding pharmacies to sell the drugs
Those who received Saxenda 3.0 mg lost an average of 8% of their body weight over 56 weeks, compared to 2.6% in the placebo group
Semaglutide is the active ingredient in weight loss drugs like Novo Nordisk's Ozempic and Wegovy, which have been hailed as "miracle drugs" for not only treating obesity but also treating weight-related ailments like diabetes and high blood pressure
